Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 3 Resectable Pancreatic Cancer 1 Pancreatic Ductal Adenocarcinoma 1 Adenocarcinoma of the Pancreas 1 Adenocarcinoma 1

Interventions

Oxaliplatin 19 pembrolizumab 13 Fluorouracil 12 Leucovorin 11 Capecitabine 11 Paclitaxel 10 Gemcitabine 8 Docetaxel 8 zolbetuximab 6 cemiplimab 6 Cisplatin 6 Albumin-Bound Paclitaxel 6 durvalumab 5 Ramucirumab 5 Radiotherapy 5 Irinotecan 4 Cyclophosphamide 4 130-nm albumin-bound paclitaxel 4 trastuzumab deruxtecan 3 tislelizumab 3 lenvatinib 3 enzalutamide 3 darolutamide 3 Trastuzumab 3 Taxes 3 S 1 (combination) 3 Radiosurgery 3 Pemetrexed 3 Nivolumab 3 Carboplatin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Adenocarcinoma × paricalcitol × 1 year × Clear all

NCT03415854 2026-05-12

NABPLAGEMD

HonorHealth Research Institute

Phase 2 Completed

34 enrolled 11 charts

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡